Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

IMV Inc. to Present at Two Upcoming Investor Events: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. to Present at Two Upcoming Investor Events


IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers today

Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences.




  • H.C. Wainwright

IMV Appoints Andrew Hall as Chief Executive Officer: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Appoints Andrew Hall as Chief Executive Officer


IMV Inc. (NASDAQ: IMV; TSX: IMV), (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tumors and

IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today

IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers, today

Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced

Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and blood cancers, today announced

IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer


IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and blood cancers while preserving

EnWave Signs Royalty-Bearing Commercial License Agreement and Equipment Purchase Agreement with Nippon Trends Food Services, Inc.
EnWave Signs Royalty-Bearing Commercial License Agreement and Equipment Purchase Agreement with Nippon Trends Food Services, Inc.

 

Vancouver, B.C., December 1, 2020. EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) announced

EnWave unterzeichnet zweiten Anlagenkaufvertrag mit Patata Torres um die REV™ Fertigungskapazität um 100kW zu erhöhen
EnWave Signs Second Equipment Purchase Agreement with Patata Torres to Increase REV™ Manufacturing Capacity by 100kW
EnWave Signs Second Equipment Purchase Agreement with Patata Torres to Increase REV™ Manufacturing Capacity by 100kW

 

Vancouver, B.C., November 30, 2020

EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced

EnWave Appoints Mr. Pablo Cussatti to its Board of Directors, Announces Retirement of Director, Mr. Hugh McKinnon
EnWave Appoints Mr. Pablo Cussatti to its Board of Directors, Announces Retirement of Director, Mr. Hugh McKinnon

Vancouver, B.C., November 20, 2020

EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/), announced today

EnWave beruft Pablo Cussatti in den Verwaltungsrat und kündigt Rücktritt des Direktors Hugh McKinnon an
EnWave beruft Pablo Cussatti in den Verwaltungsrat und kündigt Rücktritt des Direktors Hugh McKinnon an

Vancouver, B.C., 20. November 2020

Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) gab

EnWave Sells EU-GMP 10kW REV™ Machine to Pharmaceutical Cannabis Cultivator in Europe
EnWave Sells EU-GMP 10kW REV™ Machine to Pharmaceutical Cannabis Cultivator in Europe

Vancouver, B.C., June 29, 2022 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today

EnWave verkauft EU-GMP 10kW REV™ Maschine an Pharmazeutischen Cannabiszüchter in Europa
EnWave verkauft EU-GMP 10kW REV™ Maschine an Pharmazeutischen Cannabiszüchter in Europa

Vancouver, B.C., 29. Juni 2022 - EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab heute

EnWave verkauft 10kW Maschine an Fungaria Snack Ltd. für Obst- und Gemüseproduktion in Ungarn
EnWave verkauft 10kW Maschine an Fungaria Snack Ltd. für Obst- und Gemüseproduktion in Ungarn

Vancouver, B.C., 28. Juni 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab

EnWave Sells 10kW Machine to Fungaria Snack Ltd.  for Fruit and Vegetable Production in Hungary
EnWave Sells 10kW Machine to Fungaria Snack Ltd. for Fruit and Vegetable Production in Hungary

Vancouver, B.C., June 28, 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today

EnWave verkauft dritte 10-kW-REV™-Maschine an Dairy Concepts IRL und erhöht damit weiter die Kapazität für die Produktion von lagerstabilen Molkereisnacks
EnWave verkauft dritte 10-kW-REV™-Maschine an Dairy Concepts IRL und erhöht damit weiter die Kapazität für die Produktion von lagerstabilen Molkereisnacks

Vancouver, B.C., 27. Juni 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) ("EnWave") gab bekannt, dass Dairy Concepts IRL ("DCI"), ein aufstrebender Marktführer im Bereich innovativer

EnWave veranstaltet Showcase-Event mit Elea, um die Synergien der PEF- und REV™-Technologien hervorzuheben
EnWave veranstaltet Showcase-Event mit Elea, um die Synergien der PEF- und REV™-Technologien hervorzuheben

Vancouver, British Columbia, 13. April 2022 - EnWave Corporation (TSX-V:ENW | FSE:E4U) („EnWave“ oder das „Unternehmen“ - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/)